Literature DB >> 21154529

Synthesis of peptidomimetic conjugates of cyclic nucleoside phosphonates.

Michaela Serpi1, Ivan S Krylov, Valeria M Zakharova, Charles E McKenna.   

Abstract

Cyclic nucleoside phosphonates connected through a P-O-C linkage to a promoiety represent a class of prodrugs designed to overcome the low oral bioavailability of parent antiviral acyclic nucleoside phosphonates. In our prodrug approach, a nontoxic promoiety, such as an amino acid or dipeptide, is conjugated to the cyclic form of the parent drug by esterification of the phosphonic acid moiety with an alcoholic amino acid side chain (Ser, Tyr, and Thr) or a glycol linker. For the biological evaluation and investigation of the pharmacokinetic profiles of these modified nucleoside phosphonates, a reliable synthetic procedure that allows preparation of sufficient amount of potential prodrugs is needed. This unit provides a procedure for synthesizing peptidomimetic conjugates of two broad-spectrum antiviral acyclic nucleoside phosphonates: (S)-HPMPC and (S)-HPMPA. Two alternate strategies allowing synthesizing selected amino acid, dipeptide, or ethylene glycol-linked amino acid prodrugs of (S)-HPMPC and (S)-HPMPA in solution and using a solid-phase approach are presented.
© 2010 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21154529      PMCID: PMC3056568          DOI: 10.1002/0471142700.nc1504s43

Source DB:  PubMed          Journal:  Curr Protoc Nucleic Acid Chem        ISSN: 1934-9270


  9 in total

Review 1.  The acyclic nucleoside phosphonates from inception to clinical use: historical perspective.

Authors:  Erik De Clercq
Journal:  Antiviral Res       Date:  2006-11-07       Impact factor: 5.970

2.  Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.

Authors:  D B Mendel; T Cihlar; K Moon; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 3.  Acyclic nucleoside phosphonates: a key class of antiviral drugs.

Authors:  Erik De Clercq; Antonín Holý
Journal:  Nat Rev Drug Discov       Date:  2005-11       Impact factor: 84.694

4.  Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir.

Authors:  Ulrika Eriksson; John M Hilfinger; Jae-Seung Kim; Stefanie Mitchell; Paul Kijek; Katherine Z Borysko; Julie M Breitenbach; John C Drach; Boris A Kashemirov; Charles E McKenna
Journal:  Bioorg Med Chem Lett       Date:  2006-11-10       Impact factor: 2.823

Review 5.  Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues.

Authors:  Larryn W Peterson; Charles E McKenna
Journal:  Expert Opin Drug Deliv       Date:  2009-04       Impact factor: 6.648

6.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

Authors:  Karl Y Hostetler
Journal:  Antiviral Res       Date:  2009-05       Impact factor: 5.970

7.  Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity.

Authors:  Ulrika Eriksson; Larryn W Peterson; Boris A Kashemirov; John M Hilfinger; John C Drach; Katherine Z Borysko; Julie M Breitenbach; Jae Seung Kim; Stefanie Mitchell; Paul Kijek; Charles E McKenna
Journal:  Mol Pharm       Date:  2008-05-16       Impact factor: 4.939

8.  Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.

Authors:  J Soul-Lawton; E Seaber; N On; R Wootton; P Rolan; J Posner
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 9.  Phosphonomethoxyalkyl analogs of nucleotides.

Authors:  Antonín Holy
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.